Search
Cookie policy
Introduction
When you visit the EHA website and/or EHA’s resource platform(s) (this includes all websites and pages, with the exemption of www. t2evolve.
‘Rare Cancers in all EU policies’: Prof Elizabeth Macintyre expresses strong EHA support for the Rare Cancers Europe agenda
On September 28, EHA President Elizabeth Macintyre addressed an audience that included Members of the European Parliament, and officials of the European Commission and the European Medicines Agency, as well as members of the Rare Cancers Europe (RCE) partnership.
Read moreMyeloproliferative neoplasms better understood through scientific meeting
The EHA-SWG Scientific Meeting on Challenges in the Diagnosis and Management of Myeloproliferative Neoplasms held on October 12-14, 2017 in Budapest, Hungary received a 100% recommendation rating from attendees.
Read moreMajor research funding calls are out now
First, the Innovative Medicines Initiative published its final call under the EU Seventh Framework Programme. Interestingly for hematologists, the call includes a project called ‘Blood-based biomarker assays for personalized tumour therapy: value of circulating biomarkers’.
Read moreHemaSphere Editorial Board
Editor-in-Chief
Jan Cools, Belgium
Deputy Editor-in-Chief
Claire Harrison, United Kingdom
Associate Editors
Jeroen Eikenboom, The Netherlands
Simone Ferrero (Italy)
Adele Fielding, United Kingdom
Simon Hallam, United Kingdom
Robert Hills, United Kingdom
Steffen Koschmieder, Germany
Marek Mraz (Czech Republic)
Paula Rodríguez Otero, Spain
Juerg Schwaller, Switzerland
Francesca Vinchi, USA
Scientific Editors
Charles de Bock, Australia
Stephen Hibbs, United…
Tackling Sickle Cell Disease: the need for a European approach
Elvie Ingoli, president of the German association of SCD and thalassemia patients, at the 7th EAPM Presidency Conference in Brussels. Sickle Cell Disease (SCD) is relatively new to many parts of Europe.
Read moreRegulation on Health Technology Assessment
The Regulation on Health Technology Assessment (HTAR) was proposed by the European Commission in 2018. It was formally adopted in December 2021 and will apply from January 2025.
Read more